JP2019536462A5 - - Google Patents

Download PDF

Info

Publication number
JP2019536462A5
JP2019536462A5 JP2019530105A JP2019530105A JP2019536462A5 JP 2019536462 A5 JP2019536462 A5 JP 2019536462A5 JP 2019530105 A JP2019530105 A JP 2019530105A JP 2019530105 A JP2019530105 A JP 2019530105A JP 2019536462 A5 JP2019536462 A5 JP 2019536462A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
genome editing
cas9 protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019530105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536462A (ja
JP7272952B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/064720 external-priority patent/WO2018106693A1/en
Publication of JP2019536462A publication Critical patent/JP2019536462A/ja
Publication of JP2019536462A5 publication Critical patent/JP2019536462A5/ja
Priority to JP2022208855A priority Critical patent/JP2023052089A/ja
Application granted granted Critical
Publication of JP7272952B2 publication Critical patent/JP7272952B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019530105A 2016-12-05 2017-12-05 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法 Active JP7272952B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022208855A JP2023052089A (ja) 2016-12-05 2022-12-26 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662430154P 2016-12-05 2016-12-05
US62/430,154 2016-12-05
US201762503640P 2017-05-09 2017-05-09
US62/503,640 2017-05-09
PCT/US2017/064720 WO2018106693A1 (en) 2016-12-05 2017-12-05 SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022208855A Division JP2023052089A (ja) 2016-12-05 2022-12-26 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法

Publications (3)

Publication Number Publication Date
JP2019536462A JP2019536462A (ja) 2019-12-19
JP2019536462A5 true JP2019536462A5 (https=) 2021-01-21
JP7272952B2 JP7272952B2 (ja) 2023-05-12

Family

ID=60972337

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019530105A Active JP7272952B2 (ja) 2016-12-05 2017-12-05 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法
JP2022208855A Withdrawn JP2023052089A (ja) 2016-12-05 2022-12-26 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022208855A Withdrawn JP2023052089A (ja) 2016-12-05 2022-12-26 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法

Country Status (9)

Country Link
US (6) US9963719B1 (https=)
EP (1) EP3548614A1 (https=)
JP (2) JP7272952B2 (https=)
KR (1) KR102604903B1 (https=)
CN (1) CN110168084A (https=)
AU (1) AU2017373797B2 (https=)
CA (1) CA3046076A1 (https=)
MX (2) MX2019006475A (https=)
WO (1) WO2018106693A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
CN115491373A (zh) * 2015-10-30 2022-12-20 爱迪塔斯医药公司 治疗单纯疱疹病毒的crispr/cas相关方法及组合物
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CA3082450A1 (en) 2017-11-21 2019-05-31 Crispr Therapeutics Ag Materials and methods for treatment of autosomal dominant retinitis pigmentosa
WO2019118875A1 (en) * 2017-12-15 2019-06-20 Ou Li Crispr-mediated genome editing with vectors
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
US12227547B2 (en) 2018-09-10 2025-02-18 The Regents Of The University Of California Modulators of CAS9 polypeptides and methods of use thereof
CA3130515A1 (en) 2019-02-25 2020-09-03 Editas Medicine, Inc. Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)
SG11202109741VA (en) * 2019-03-12 2021-10-28 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
MA56393A (fr) * 2019-06-28 2022-05-04 Bayer Healthcare Llc Matériels et méthodes de régulation de l'édition de gènes
WO2021053582A1 (en) * 2019-09-18 2021-03-25 Crispr Therapeutics Ag All-in-one self inactivating crispr vectors
WO2021062201A1 (en) * 2019-09-25 2021-04-01 Spotlight Therapeutics Compositions and methods for nucleoprotein targeting and expression
CA3180775A1 (en) * 2020-05-29 2021-12-16 Regents Of The University Of Minnesota Copolymers for intracellular therapeutic nucleic acid payload delivery
AU2021391783A1 (en) * 2020-12-03 2023-06-22 Scribe Therapeutics Inc. Compositions and methods for the targeting of bcl11a
WO2022221741A1 (en) 2021-04-16 2022-10-20 Editas Medicine, Inc. Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)
WO2025179057A1 (en) * 2024-02-21 2025-08-28 The Regents Of The University Of California In vivo modification of cell genomes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
JP6712948B2 (ja) * 2013-12-12 2020-06-24 ザ・ブロード・インスティテュート・インコーポレイテッド 組成物、及びヌクレオチドリピート障害におけるcrispr−cas系の使用方法
ES2745769T3 (es) 2014-03-10 2020-03-03 Editas Medicine Inc Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10)
EP4464338A3 (en) 2014-11-07 2025-02-12 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
KR20230156800A (ko) * 2015-03-03 2023-11-14 더 제너럴 하스피탈 코포레이션 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
WO2016176404A1 (en) * 2015-04-30 2016-11-03 The Brigham And Women's Hospital, Inc. Methods and kits for cloning-free genome editing
US20180291372A1 (en) * 2015-05-14 2018-10-11 Massachusetts Institute Of Technology Self-targeting genome editing system
BR112017024514A2 (pt) 2015-05-16 2018-07-24 Genzyme Corporation edição genética de mutações intrônicas profundas
WO2017136335A1 (en) 2016-02-01 2017-08-10 The Regents Of The University Of California Self-inactivating endonuclease-encoding nucleic acids and methods of using the same
WO2017173004A1 (en) * 2016-03-30 2017-10-05 Mikuni Takayasu A method for in vivo precise genome editing

Similar Documents

Publication Publication Date Title
JP2019536462A5 (https=)
JP2022519507A5 (https=)
JP2023540797A5 (https=)
US20200340012A1 (en) Crispr-cas genome engineering via a modular aav delivery system
CN111757889A (zh) 新型CRISPR/Cas12f酶和系统
MX2023002848A (es) Enzimas modificadoras del acido desoxirribonucleico (adn) y fragmentos activos y sus variantes y metodos de uso.
JP2022529329A (ja) 人工的に構築されたrna編集酵素による部位特異的rna編集および関連使用
JP2019531068A5 (https=)
JP2019526248A5 (https=)
JP2017513479A5 (https=)
JP2018534950A5 (https=)
IL309801B1 (en) Using nucleosome interacting protein domains to enhance targeted genome modification
KR20180012834A (ko) 두 개의 벡터로부터 발현된 Cas9 단백질을 이용한 유전자 발현 조절 방법
NO20081233L (no) Albumin fusjonsproteiner
JP2017018125A5 (https=)
JP2018537087A5 (https=)
DK1641818T3 (da) Polypeptider der har bindingsaffinitet for HER2
WO2005080556A3 (en) Virus purification methods
JP2015532654A5 (https=)
JP2018520997A5 (https=)
DE602005016712D1 (de) Rter dna
ZA200007403B (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals.
JP2015513897A5 (https=)
JP2015521465A5 (https=)
MX2021004714A (es) Proteina cas9 modificada, y uso de la misma.